General Information of Drug (ID: DMWH7Z5)

Drug Name
BI-836826 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMWH7Z5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Otlertuzumab DMAZIND Chronic lymphocytic leukaemia 2A82.0 Phase 2 [1]
IMGN529 DMNJ491 Non-hodgkin lymphoma 2B33.5 Phase 2 [4]
Naratuximab emtansine DMSWUNX Diffuse large B-cell lymphoma 2A81 Phase 2 [5]
TRU-016 DM9IQ4A Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [6]
GEN3009 DMD8RLY B-cell non-hodgkin lymphoma 2B33.5 Phase 1/2 [7]
212Pb-labelled aCD37 DMLVADH leukaemia 2A60-2B33 Preclinical [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte antigen CD37 (CD37) TTFCW29 CD37_HUMAN Not Available [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61.
4 The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
5 Clinical pipeline report, company report or official report of Debiopharm.
6 TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90.
7 Clinical pipeline report, company report or official report of AbbVie.
8 Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.